Physician profile
Todd D Daugherty
NPI 1639390776
$21,664.74
in general payments reported to CMS, 2019-2025
30 companies · $4,166 in 2025
The $4,166 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $6,096 · 2021: $1,457 · 2022: $2,856 · 2023: $1,713 · 2024: $4,352 · 2025: $4,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,856 · Consulting Fee: $2,078 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,855.99 |
| Consulting Fee | $2,077.50 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,492.74 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,940.63 | 2019-2025 | Krystexxa, Uplizna, Enbrel |
| Horizon Therapeutics Plc | $1,804.77 | 2022-2023 | Krystexxa, Tepezza |
| Janssen Global Services, LLC | $1,500.00 | 2020 | |
| Ucb, INC. | $1,336.50 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Scientific Affairs, LLC | $1,092.53 | 2019-2024 | Tremfya |
| Abbvie INC. | $955.91 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $599.96 | 2021-2025 | Taltz, Omvoh |
| E.R. Squibb & Sons, L.L.C. | $534.34 | 2019-2025 | Orencia, Sotyktu |
| Mallinckrodt Hospital Products INC. | $533.20 | 2023-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $479.89 | 2019-2025 | |
| Pfizer INC. | $375.44 | 2022-2025 | |
| Johnson & Johnson Health Care Systems INC. | $285.49 | 2019-2024 | Simponi Aria, Tremfya |
| Astrazeneca Pharmaceuticals LP | $280.91 | 2021-2025 | Saphnelo |
| Sobi, INC | $149.68 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $137.35 | 2024 | |
| Ani Pharmaceuticals, INC. | $130.21 | 2025 | Purified Cortrophin Gel |
| Organon LLC | $128.76 | 2023-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $124.58 | 2020-2024 | Nucala, Benlysta |
| Genentech, INC. | $119.85 | 2019 | |
| Tersera Therapeutics LLC | $117.03 | 2025 | Quzyttir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.52 | 2023-2025 | Cyltezo |
| Radius Health, INC. | $92.78 | 2024-2025 | Tymlos |
| Invivyd INC | $82.38 | 2025 | Pemgarda |
| Genentech USA, INC. | $70.53 | 2021-2025 | Actemra |
| Fresenius Kabi USA, LLC | $60.76 | 2025 | Tyenne |
| Cardinal Health INC | $56.36 | 2024 | |
| Sandoz INC. | $32.26 | 2024-2025 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $28.37 | 2024 | Uptravi |
| Kyowa Kirin, INC. | $15.01 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.